145 related articles for article (PubMed ID: 30500933)
21. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
Zhao H; Wang S; Song C; Zha Y; Li L
World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166
[TBL] [Abstract][Full Text] [Related]
22. The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis.
Lee A; Youssef I; Osborn VW; Safdieh J; Becker DJ; Schreiber D
J Clin Neurosci; 2018 May; 51():85-90. PubMed ID: 29483008
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
[TBL] [Abstract][Full Text] [Related]
25. Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.
Schiffgens S; Wilkens L; Brandes AA; Meier T; Franceschi E; Ermani M; Hartmann C; Sandalcioglu IE; Dumitru CA
Oncotarget; 2016 Aug; 7(34):55169-55180. PubMed ID: 27409829
[TBL] [Abstract][Full Text] [Related]
26. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
28. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
29. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
31. The significance of MGMT methylation in Glioblastoma Multiforme prognosis.
Rao AM; Quddusi A; Shamim MS
J Pak Med Assoc; 2018 Jul; 68(7):1137-1139. PubMed ID: 30317322
[TBL] [Abstract][Full Text] [Related]
32. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
[TBL] [Abstract][Full Text] [Related]
34. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
35. Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue.
Araki Y; Mizoguchi M; Yoshimoto K; Shono T; Amano T; Nakamizo A; Suzuki SO; Iwaki T; Sasaki T
Brain Tumor Pathol; 2011 Feb; 28(1):25-31. PubMed ID: 21249460
[TBL] [Abstract][Full Text] [Related]
36. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
[TBL] [Abstract][Full Text] [Related]
37. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
38. MGMT Promoter Methylation Status Is Not Related to Histological or Radiological Features in IDH Wild-type Glioblastomas.
Mikkelsen VE; Dai HY; Stensjøen AL; Berntsen EM; Salvesen Ø; Solheim O; Torp SH
J Neuropathol Exp Neurol; 2020 Aug; 79(8):855-862. PubMed ID: 32688383
[TBL] [Abstract][Full Text] [Related]
39. The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma.
Villani V; Casini B; Pace A; Prosperini L; Carapella CM; Vidiri A; Fabi A; Carosi M
Dis Markers; 2015; 2015():604719. PubMed ID: 26347581
[TBL] [Abstract][Full Text] [Related]
40. An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity.
Nguyen A; Legrain M; Noel G; Coca A; Meyer Ea N; Schott R; Lasthaus C; Chenard MP; Gaub MP; Lessinger JM; Guenot D; Entz-Werle N
Curr Cancer Drug Targets; 2015; 15(7):624-40. PubMed ID: 26118907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]